Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.4 | uM | 12000.155 | 0.9530 | 0.8911 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 2 | uM | 12000.155 | 0.8681 | 0.6964 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 10 | uM | 12000.155 | 0.8189 | 0.5851 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 50 | uM | 12000.155 | 0.7425 | 0.4143 | 0.8592 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.000128 | uM | 12084.155 | 1.0399 | 1.0613 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.00064 | uM | 12084.155 | 0.9688 | 0.9517 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.0032 | uM | 12084.155 | 1.0589 | 1.0904 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.016 | uM | 12084.155 | 1.0185 | 1.0285 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.08 | uM | 12084.155 | 0.9792 | 0.9678 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 0.4 | uM | 12084.155 | 1.0509 | 1.0781 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 2 | uM | 12084.155 | 0.9174 | 0.8712 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 10 | uM | 12084.155 | 0.9890 | 0.9830 | 1.2955 | |
| HCC1395 | TNBC | Basal B | Selumetinib | MEK | MAPK | 50 | uM | 12084.155 | 0.8971 | 0.8393 | 1.2955 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 0.000128 | uM | 12001.155 | 0.9558 | 0.8541 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 0.00064 | uM | 12001.155 | 0.9641 | 0.8812 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 0.0032 | uM | 12001.155 | 0.9430 | 0.8130 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 0.016 | uM | 12001.155 | 0.9700 | 0.9005 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 0.08 | uM | 12001.155 | 0.9383 | 0.7976 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 0.4 | uM | 12001.155 | 0.8730 | 0.5933 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 2 | uM | 12001.155 | 0.8706 | 0.5859 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 10 | uM | 12001.155 | 0.8504 | 0.5246 | 0.5973 | |
| HCC1419 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 50 | uM | 12001.155 | 0.8114 | 0.4094 | 0.5973 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.000128 | uM | 10693.146 | 0.9961 | 0.9912 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.00064 | uM | 10693.146 | 0.9507 | 0.8885 | 0.8826 | |
| HCC1428 | HR+ | Luminal | Selumetinib | MEK | MAPK | 0.0032 | uM | 10693.146 | 0.9983 | 0.9962 | 0.8826 |